Holen Sie sich die Stockscreener-App
32.14
1.04%
0.33
Vorhandelsmarkt:
32.24
0.10
+0.31%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TEVA?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$31.81
Offen:
$31.9
24-Stunden-Volumen:
12.15M
Relative Volume:
1.13
Marktkapitalisierung:
$36.87B
Einnahmen:
$16.88B
Nettoeinkommen (Verlust:
$666.71M
KGV:
52.41
EPS:
0.6132
Netto-Cashflow:
$251.19M
1W Leistung:
+1.20%
1M Leistung:
+0.78%
6M Leistung:
+94.32%
1J Leistung:
+48.25%
1-Tages-Spanne:
$31.62
$32.20
1-Wochen-Bereich:
$30.70
$32.20
52-Wochen-Spanne:
$12.46
$33.42
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
Firmenname
Teva Pharmaceutical Industries Ltd Adr
Sektor
Telefon
972 (3) 914-8213
Adresse
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Vergleichen Sie TEVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.14 | 36.50B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
ZTS
Zoetis Inc
|
123.92 | 54.67B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.61 | 51.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.37 | 46.58B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
UTHR
United Therapeutics Corp
|
473.36 | 20.19B | 3.08B | 1.24B | 1.07B | 25.61 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-12-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-05-28 | Eingeleitet | Truist | Buy |
| 2025-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-07-10 | Hochstufung | Argus | Hold → Buy |
| 2024-03-08 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-12 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-11-27 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-06 | Hochstufung | UBS | Sell → Neutral |
| 2023-05-25 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-05-18 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-01-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-11-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Herabstufung | UBS | Neutral → Sell |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-06-14 | Fortgesetzt | UBS | Neutral |
| 2022-05-17 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-05-04 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-03-25 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | Herabstufung | Argus | Buy → Hold |
| 2021-10-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | Herabstufung | UBS | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | Eingeleitet | Oppenheimer | Perform |
| 2020-08-06 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-07-27 | Fortgesetzt | Goldman | Neutral |
| 2020-06-01 | Hochstufung | SunTrust | Hold → Buy |
| 2020-04-24 | Fortgesetzt | Citigroup | Neutral |
| 2020-04-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-02-24 | Herabstufung | Edward Jones | Hold → Sell |
| 2019-11-12 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-10-17 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-08-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-19 | Eingeleitet | Wolfe Research | Peer Perform |
| 2019-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-07-05 | Hochstufung | Argus | Hold → Buy |
| 2019-06-11 | Eingeleitet | Barclays | Underweight |
| 2019-06-03 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | Herabstufung | UBS | Buy → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2019-03-07 | Fortgesetzt | UBS | Buy |
Alle ansehen
Teva Pharmaceutical Industries Ltd Adr Aktie (TEVA) Neueste Nachrichten
Assessing Teva (TEVA) Valuation As Guidance Driven Momentum Lifts Long Term Profit Expectations - Sahm
The Truth About Teva Pharmaceutical (ADR): Why Everyone Is Suddenly Watching This Stock - AD HOC NEWS
Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results? - Finviz
Sodium Chloride Injections Market, Global Forecast 2026-2032 - GlobeNewswire Inc.
How Long-Term Profit Targets and TEV-‘408 Funding At Teva Pharmaceutical (TEVA) Has Changed Its Investment Story - Sahm
Is Teva (TEVA) Still Reasonably Priced After A 195% Three Year Share Price Gain - Sahm
Judge Denies Teva Bid To Pause Paragard Copper Contraceptive Device Lawsuit Trial - Benzinga
Assessing Teva Pharmaceutical Industries (TEVA) Valuation After A Sharp Multi‑Month Share Price Rally - Sahm
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug - Finviz
Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug - Sahm
Truist Lifts PT on Teva Pharmaceutical Industries (TEVA) to $36 From $32 - Finviz
Should Teva’s Q3 Beat and New Schizophrenia and Denosumab Moves Require Action From TEVA Investors? - Sahm
Is Teva Pharmaceutical Industries (TEVA) Still Attractive After A 49% One Year Share Price Jump - Sahm
Teva stock hits 52-week high at $32.02 - Investing.com
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Teva Pharmaceutical Industries (NYSE:TEVA): Assessing Valuation After a 46% Share Price Rebound - Sahm
Top 2 Health Care Stocks That May Crash In Q1 - Sahm
Teva Pharmaceutical (ADR) Is Popping Off: Smart Buy or Overhyped Trap? - AD HOC NEWS
Teva Pharmaceutical (ADR): Bracing For 2026 After A Volatile Year Of Legal Wins, Debt Cuts And A Re- - AD HOC NEWS
The Truth About Teva Pharmaceutical (ADR): Is This ‘Boring’ Stock Quietly Going Viral with Inves - AD HOC NEWS
The Truth About Teva Pharmaceutical (ADR): Is Wall Street Sleeping on This Comeback Play? - AD HOC NEWS
What Do Analysts Think About Teva Pharmaceutical Industries (TEVA)? - Finviz
Has Teva’s Surging Share Price Outpaced Its Long Term Recovery Prospects? - Sahm
S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive - Sahm
J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play - Finviz
Teva Pharma stock hits 52-week high at 30.45 USD By Investing.com - Investing.com Australia
Teva Pharma stock hits 52-week high at 30.45 USD - Investing.com India
Teva (TEVA): Assessing Valuation After a 65% Three‑Month Share Price Surge - Sahm
BofA Raises Teva Pharmaceuticals Industries Limited (TEVA) Target to $32 as Barclays Initiates Overweight - Finviz
FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock? - Finviz
Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead? - Finviz
Has Teva’s 80% One Year Surge Run Ahead of Its Fundamental Valuation in 2025? - Sahm
Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026 - Sahm
Teva Releases Q4 2025 Aide Memoire - Sahm
Teva (NYSE:TEVA) Valuation Check After New Schizophrenia Drug Filing and Growing Growth Optimism - Sahm
Teva’s FDA Filing For Once-Monthly Schizophrenia Drug Might Change The Case For Investing In TEVA - Sahm
Teva Pharma stock hits 52-week high at 29.81 USD By Investing.com - Investing.com Nigeria
Teva Pharma stock hits 52-week high at 29.81 USD - Investing.com
TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia - Finviz
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play - Finviz
Teva (NYSE:TEVA) Valuation Check After Strong Q3, Margin Targets and Deleveraging Drive a Sharp Share Price Rebound - Sahm
Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - Finviz
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December - Sahm
Is the Market Bullish or Bearish on Teva Pharmaceutical Industries Ltd? - Sahm
Teva stock hits 52-week high at 26.38 USD - Investing.com
Teva Rise Innovation Platform Might Change The Case For Investing In Teva Pharmaceutical Industries (TEVA) - Sahm
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® - Sahm
Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma's Biggest Challenges - Finviz
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Shares: Cheap or Risky? - fostersleader.com
Finanzdaten der Teva Pharmaceutical Industries Ltd Adr-Aktie (TEVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
1.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):